Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
NCT ID: NCT04485845
Last Updated: 2020-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
39 participants
INTERVENTIONAL
2019-11-01
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs.
Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
NCT03253562
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
NCT01426802
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
NCT07077525
Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
NCT03693560
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
NCT05429554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metformin treated group
A group of patients treated with a daily dose of metformin
Captopril Tablets
used to treat hypertension in metabolic syndrome patients and as a renal protector
MetFORMIN 500 Mg Oral Tablet
antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
vildagliptin treated group
A group of patients treated with a daily dose of vildagliptin
Vildagliptin
to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
Captopril Tablets
used to treat hypertension in metabolic syndrome patients and as a renal protector
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vildagliptin
to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
Captopril Tablets
used to treat hypertension in metabolic syndrome patients and as a renal protector
MetFORMIN 500 Mg Oral Tablet
antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. body mass index be-tween≥22 and ≤40 kg/m2.
3. DM with an HbA1c ≥ 7
Exclusion Criteria
\-
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dalia K. Zaafar
lecturer of pharmacology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dalia Zaafar, PhD
Role: PRINCIPAL_INVESTIGATOR
Lecturer of clinical pharmacology and toxicology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Diabetes & Endocrinology Institute
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
dalia zaafar, phd
Role: primary
soha hassanin, phd
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDE00218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.